Romero, Rodrigo http://orcid.org/0000-0002-9388-8306
Sánchez-Rivera, Francisco J. http://orcid.org/0000-0002-8466-8563
Westcott, Peter M. K.
Mercer, Kim L.
Bhutkar, Arjun
Muir, Alexander
González Robles, Tania J.
Lamboy Rodríguez, Swanny
Liao, Laura Z. http://orcid.org/0000-0002-1277-0956
Ng, Sheng Rong http://orcid.org/0000-0003-1655-2443
Li, Leanne
Colón, Caterina I.
Naranjo, Santiago
Beytagh, Mary Clare
Lewis, Caroline A. http://orcid.org/0000-0003-1787-5084
Hsu, Peggy P.
Bronson, Roderick T.
Vander Heiden, Matthew G. http://orcid.org/0000-0002-6702-4192
Jacks, Tyler http://orcid.org/0000-0001-5785-8911
Funding for this research was provided by:
Howard Hughes Medical Institute (NA)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30-CA14051, F31CA224796)
National Science Foundation (1122374)
Article History
Received: 18 July 2019
Accepted: 1 May 2020
First Online: 8 June 2020
Change Date: 21 August 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-020-00118-z
Competing interests
: M.G.V.H. is a consultant and scientific advisory board member for Agios Pharmaceuticals, Aeglea Biotherapeutics, iTeos and Auron Therapeutics. P.P.H. is a consultant for Auron Therapeutics. T.J. is a member of the Board of Directors of Amgen and Thermo Fisher Scientific. He is also a Co-founder of Dragonfly Therapeutics and T2 Biosystems. T.J. serves on the Scientific Advisory Board of Dragonfly Therapeutics, SQZ Biotech and Skyhawk Therapeutics. None of these affiliations represents a conflict of interest with respect to the design or execution of this study or interpretation of data presented in this manuscript. The laboratory of T.J. currently also receives funding from the Johnson & Johnson Lung Cancer Initiative, but this funding did not support the research described in this manuscript. This work was supported by the Howard Hughes Medical Institute and Calico Life Sciences.